Seung Tae Kim

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1117759/publications.pdf

Version: 2024-02-01

237 papers	7,589 citations	109321 35 h-index	66911 78 g-index
240 all docs	240 docs citations	240 times ranked	11554 citing authors

#	Article	IF	Citations
1	Prediction of epithelial-to-mesenchymal transition molecular subtype using CT in gastric cancer. European Radiology, 2022, 32, 1-11.	4.5	6
2	The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors. Journal of Cancer Research and Clinical Oncology, 2022, 148, 2427-2435.	2.5	5
3	Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group. Cancer Research and Treatment, 2022, 54, 1-9.	3.0	9
4	Safety and anti-tumor effects of vismodegib in patients with refractory advanced gastric cancer: A single-arm, phase-II trial. Journal of Cancer, 2022, 13, 1097-1102.	2.5	2
5	Phase 1b study of vactosertib in combination with nal-IRI plus 5FU/LV in patients with metastatic pancreatic ductal adenocarcinoma who have failed first-line gemcitabine/nab-paclitaxel.. Journal of Clinical Oncology, 2022, 40, TPS632-TPS632.	1.6	2
6	HER2 Aberrations as a Novel Marker in Advanced Biliary Tract Cancer. Frontiers in Oncology, 2022, 12, 834104.	2.8	6
7	Incidence of FGFR2 Amplification and FGFR2 Fusion in Patients with Metastatic Cancer Using Clinical Sequencing. Journal of Oncology, 2022, 2022, 1-9.	1.3	7
8	Determining Which Patients Require Preoperative Pelvic Radiotherapy Before Curative-Intent Surgery and/or Ablation for Metastatic Rectal Cancer. Annals of Surgical Oncology, 2022, , 1.	1.5	1
9	Early Tumorâ€“Immune Microenvironmental Remodeling and Response to First-Line Fluoropyrimidine and Platinum Chemotherapy in Advanced Gastric Cancer. Cancer Discovery, 2022, 12, 984-1001.	9.4	52
10	ASO Visual Abstract: Determining Which Patients Require Preoperative Pelvic Radiotherapy Before Curative Intent Surgery and/or Ablation for Metastatic Rectal Cancer. Annals of Surgical Oncology, 2022, , .	1.5	0
11	Global multi-center phase I trial of the intraperitoneal infusion of anti-EpCAM x anti-CD3 bispecific antibody catumaxomab for advanced gastric carcinoma with peritoneal metastasis.. Journal of Clinical Oncology, 2022, 40, e16102-e16102.	1.6	1
12	Prevalence of MET aberration using next generation sequencing in oncology clinic: A real-world experience.. Journal of Clinical Oncology, 2022, 40, e16099-e16099.	1.6	0
13	Comprehensive landscape of tumor angiogenesis via integrating RNA sequencing and three-dimensional microphysiological system.. Journal of Clinical Oncology, 2022, 40, e16058-e16058.	1.6	1
14	Solid tumor patients with G12V and G13D KRAS aberrations have poor survival following ICI treatment.. Journal of Clinical Oncology, 2022, 40, e14567-e14567.	1.6	0
15	Landscape of tumor mutation burden and correlation to clinical outcomes in 1,744 solid cancers.. Journal of Clinical Oncology, 2022, 40, 2667-2667.	1.6	0
16	Exosome in ascites can be a potential therapeutic target for gastric cancer with malignant ascites.. Journal of Clinical Oncology, 2022, 40, e15008-e15008.	1.6	0
17	Oxaliplatin (3 months v 6 months) With 6 Months of Fluoropyrimidine as Adjuvant Therapy in Patients With Stage II/III Colon Cancer: KCSG CO09-07. Journal of Clinical Oncology, 2022, 40, 3868-3877.	1.6	6
18	Safety and efficacy of YBL-006, an anti-PD-1 monoclonal antibody in advanced solid tumors: A phase I study.. Journal of Clinical Oncology, 2022, 40, e14557-e14557.	1.6	0

#	Article	IF	Citations
19	ARTISTRY-6: Nemvaleukin alfa monotherapy in patients with advanced mucosal and cutaneous melanoma.. Journal of Clinical Oncology, 2022, 40, TPS9609-TPS9609.	1.6	0
20	Phase 1b study of vactosertib in combination with oxaliplatin with 5FU/LV (FOLFOX) in patients with metastatic pancreatic cancer who have failed first-line gemcitabine/nab-paclitaxel.. Journal of Clinical Oncology, 2022, 40, e16299-e16299.	1.6	1
21	Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer.. Journal of Clinical Oncology, 2022, 40, 4045-4045.	1.6	0
22	Tumor microenvironment (TME) dynamics following capecitabine/oxaliplatin (CapeOx) plus pembrolizumab in patients with advanced gastric cancer.. Journal of Clinical Oncology, 2022, 40, 4053-4053.	1.6	0
23	Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer. , 2022, 10, e005041.		31
24	Prognostic significance of sarcopenia in microsatellite-stable gastric cancer patients treated with programmed death-1 inhibitors. Gastric Cancer, 2021, 24, 457-466.	5.3	34
25	Programmed Death Ligand 1 Expression as a Prognostic Marker in Patients with Advanced Biliary Tract Cancer. Oncology, 2021, 99, 365-372.	1.9	6
26	Prognostic Factors of Survival with Aflibercept and FOLFIRI (fluorouracil, leucovorin, irinotecan) as Second-line Therapy for Patients with Metastatic Colorectal Cancer. Journal of Cancer, 2021, 12, 460-466.	2.5	4
27	When to apply immune checkpoint inhibitor in patients with refractory advanced gastric cancer. Journal of Cancer, 2021, 12, 5681-5686.	2.5	0
28	Chromatin accessibility of circulating CD8+ T cells predicts treatment response to PD-1 blockade in patients with gastric cancer. Nature Communications, 2021, 12, 975.	12.8	26
29	Determinants of Response and Intrinsic Resistance to PD-1 Blockade in Microsatellite Instabilityâ€“High Gastric Cancer. Cancer Discovery, 2021, 11, 2168-2185.	9.4	105
30	A phase 1 dose-escalation and dose-expansion study to assess the safety and efficacy of CKD-516, a novel vascular disrupting agent, in combination with Irinotecan in patients with previously treated metastatic colorectal cancer. Investigational New Drugs, 2021, 39, 1335-1347.	2.6	1
31	ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma. Nature, 2021, 594, 418-423.	27.8	64
32	Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer. Clinical Cancer Research, 2021, 27, 4700-4709.	7.0	54
33	Phase II study of ceralasertib (AZD6738), in combination with durvalumab in patients with metastatic melanoma who have failed prior anti-PD-1 therapy.. Journal of Clinical Oncology, 2021, 39, 9514-9514.	1.6	4
34	Understanding Patient Experience in Biliary Tract Cancer: A Qualitative Patient Interview Study. Oncology and Therapy, 2021, 9, 557-573.	2.6	7
35	Prognostic Impact of Sarcopenia and Radiotherapy in Patients With Advanced Gastric Cancer Treated With Anti-PD-1 Antibody. Frontiers in Immunology, 2021, 12, 701668.	4.8	13
36	Abstract CT234: VASTUS - a phase 1b/2a basket trial of a new PARP inhibitor, IDX-1197, including PARP inhibitor resistant cohort. , 2021, , .		1

#	Article	IF	Citations
37	Clinical Outcomes of Neoadjuvant Chemotherapy in Colorectal Cancer Patients With Synchronous Resectable Liver Metastasis: A Propensity Score Matching Analysis. Annals of Coloproctology, 2021, 37, 244-252.	2.0	13
38	Reducing tumor invasiveness by ramucirumab and TGFâ€Î²2 receptor kinase inhibitor in a diffuseâ€type gastric cancer patientâ€derived cell model. Cancer Medicine, 2021, 10, 7253-7262.	2.8	10
39	ATM Expression as a Prognostic Marker in Patients With Advanced Biliary Tract Cancer Treated With First-line Gemcitabine and Platinum Chemotherapy. In Vivo, 2021, 35, 499-505.	1.3	1
40	Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592199299.	3.2	20
41	Comprehensive molecular characterization of gastric cancer patients from phase II second-line ramucirumab plus paclitaxel therapy trial. Genome Medicine, 2021, 13, 11.	8.2	17
42	Comprehensive molecular profiling to predict clinical outcomes in pancreatic cancer. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110384.	3.2	10
43	Analysis of intrapatient heterogeneity of circulating tumor cells at the single-cell level in the cerebrospinal fluid of a patient with metastatic gastric cancer. Journal of Cancer Research and Therapeutics, 2021, 17, 1047.	0.9	2
44	Impact of Radiotherapy on Kidney Function among Patients Who Received Adjuvant Treatment for Gastric Cancer: Logistic and Linear Regression Analyses. Cancers, 2021, 13, 59.	3.7	8
45	The Impact of Tumor Mutation Burden on the Effect of Frontline Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Advanced Gastric Cancers. Frontiers in Oncology, 2021, 11, 792340.	2.8	3
46	Tumor Mutational Burden as a Biomarker for Advanced Biliary Tract Cancer. Technology in Cancer Research and Treatment, 2021, 20, 153303382110623.	1.9	11
47	A Randomized Controlled Trial of Epidermal Growth Factor Ointment for Treating Epidermal Growth Factor Receptor Inhibitor-Induced Skin Toxicities. Oncologist, 2020, 25, e186-e193.	3.7	10
48	PD-L1 expression in gastric cancer determined by digital image analyses: pitfalls and correlation with pathologist interpretation. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 243-250.	2.8	16
49	Correlation between RICTOR overexpression and amplification in advanced solid tumors. Pathology Research and Practice, 2020, 216, 152734.	2.3	6
50	Pemetrexed/Erlotinib as a Salvage Treatment in Patients with High EGFR-Expressing Metastatic Colorectal Cancer Following Failure of Standard Chemotherapy: A Phase II Single-Arm Prospective Study. Targeted Oncology, 2020, 15, 67-73.	3.6	1
51	Tumor-promoting macrophages prevail in malignant ascites of advanced gastric cancer. Experimental and Molecular Medicine, 2020, 52, 1976-1988.	7.7	53
52	Effect of baseline sarcopenia on adjuvant treatment for D2 dissected gastric cancer: Analysis of the ARTIST phase III trial. Radiotherapy and Oncology, 2020, 152, 19-25.	0.6	9
53	First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592092679.	3.2	9
54	Clinical and molecular distinctions in patients with refractory colon cancer who benefit from regorafenib treatment. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592096584.	3.2	8

#	Article	IF	Citations
55	Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer. Translational Cancer Research, 2020, 9, 3367-3374.	1.0	26
56	A Pilot Study of Baseline Spatial Genomic Heterogeneity in Primary Gastric Cancers Using Multi-Region Endoscopic Sampling. Frontiers in Oncology, 2020, 10, 225.	2.8	7
57	Antitumor activity and safety of sirolimus for solid tumors with PIK3CA mutations: A multicenter, open-label, prospective single-arm study (KM 02-01, KCSG UN17-16). Translational Cancer Research, 2020, 9, 3222-3230.	1.0	3
58	TPK1 as a predictive marker for the anti-tumour effects of simvastatin in gastric cancer. Pathology Research and Practice, 2020, 216, 152820.	2.3	6
59	Detection of Fusion Genes Using a Targeted RNA Sequencing Panel in Gastrointestinal and Rare Cancers. Journal of Oncology, 2020, 2020, 1-8.	1.3	7
60	High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features. Pathology Research and Practice, 2020, 216, 152881.	2.3	67
61	High-level FGFR2 amplification is associated with poor prognosis and Lower response to chemotherapy in gastric cancers. Pathology Research and Practice, 2020, 216, 152878.	2.3	21
62	Comprehensive pharmacogenomic characterization of gastric cancer. Genome Medicine, 2020, 12, 17.	8.2	20
63	Use of Gefitinib in EGFR-Amplified Refractory Solid Tumors: An Open-Label, Single-Arm, Single-Center Prospective Pilot Study. Targeted Oncology, 2020, 15, 185-192.	3.6	5
64	CDH1 mutations in gastric cancers are not associated with family history. Pathology Research and Practice, 2020, 216, 152941.	2.3	4
65	Clinical scoring system for the prediction of survival of patients with advanced gastric cancer. ESMO Open, 2020, 5, e000670.	4.5	17
66	Outcomes of Radiotherapy for Mesenchymal and Non-Mesenchymal Subtypes of Gastric Cancer. Cancers, 2020, 12, 943.	3.7	5
67	Tumor Mutational Burden Determined by Panel Sequencing Predicts Survival After Immunotherapy in Patients With Advanced Gastric Cancer. Frontiers in Oncology, 2020, 10, 314.	2.8	62
68	Mechanisms of Acquired Resistance to Savolitinib, a Selective MET Inhibitor in MET-Amplified Gastric Cancer. JCO Precision Oncology, 2020, 4, 222-232.	3.0	16
69	Impact of Prior Ramucirumab Use on Treatment Outcomes of Checkpoint Inhibitors in Advanced Gastric Cancer Patients. Targeted Oncology, 2020, 15, 203-209.	3.6	3
70	Association of serine/threonine kinase 11 mutations and response to programmed cell death 1 inhibitors in metastatic gastric cancer. Pathology Research and Practice, 2020, 216, 152947.	2.3	11
71	Results from a phase I, open-label study of ceralasertib (AZD6738), a novel DNA damage repair agent, in combination with weekly paclitaxel in refractory cancer (NCT02630199).. Journal of Clinical Oncology, 2020, 38, 3503-3503.	1.6	12
72	Molecular features for selecting Asian metastatic melanoma patients who benefit from check-point inhibitors.. Journal of Clinical Oncology, 2020, 38, e22011-e22011.	1.6	0

#	Article	IF	Citations
73	Novel target discovery in pembrolizumab-resistant gastric cancer using a comprehensive RNA-seq analysis pipeline.. Journal of Clinical Oncology, 2020, 38, e16541-e16541.	1.6	0
74	A clinical scoring system for survival prediction in advanced gastric cancer.. Journal of Clinical Oncology, 2020, 38, 436-436.	1.6	0
75	Pemetrexed plus erlotinib as a salvage treatment in high EGFR-expressing metastatic colorectal cancer patients following failure of standard chemotherapy: A phase II single-arm prospective study.. Journal of Clinical Oncology, 2020, 38, 104-104.	1.6	0
76	The use of regorafenib for patients with refractory metastatic colorectal cancer in clinical practice. OncoTargets and Therapy, 2019, Volume 12, 225-231.	2.0	4
77	Comprehensive molecular and clinical characterization of Asian melanoma patients treated with anti-PD-1 antibody. BMC Cancer, 2019, 19, 805.	2.6	9
78	Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel. Clinical Cancer Research, 2019, 25, 7035-7045.	7.0	152
79	High delta-like ligand 4 expression correlates with a poor clinical outcome in gastric cancer. Journal of Cancer, 2019, 10, 3172-3178.	2.5	9
80	The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma. Journal of Cancer, 2019, 10, 3140-3144.	2.5	5
81	Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial. Cancer Discovery, 2019, 9, 1388-1405.	9.4	155
82	FGFR2-Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape. Oncologist, 2019, 24, 1462-1468.	3.7	16
83	Clinical Outcomes and the Role of Adjuvant Concurrent Chemoradiation Therapy in D2-resected LN-positive Young Patients (â‰45 Years) With Gastric Cancer. Anticancer Research, 2019, 39, 5811-5820.	1.1	6
84	Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients. Scientific Reports, 2019, 9, 15365.	3.3	54
85	Cancer Panel Assay for Precision Oncology Clinic: Results from a 1-Year Study. Translational Oncology, 2019, 12, 1488-1495.	3.7	6
86	Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591987112.	3.2	27
87	Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial. Translational Oncology, 2019, 12, 597-601.	3.7	8
88	Tumor Heterogeneity Index to Detect Human Epidermal Growth Factor Receptor 2 Amplification by Next-Generation Sequencing. Journal of Molecular Diagnostics, 2019, 21, 612-622.	2.8	9
89	CCNE1 amplification is associated with liver metastasis in gastric carcinoma. Pathology Research and Practice, 2019, 215, 152434.	2.3	22
90	Selective colony area method for heterogeneous patient-derived tumor cell lines in anti-cancer drug screening system. PLoS ONE, 2019, 14, e0215080.	2.5	2

#	Article	IF	Citations
91	Prognostic Impact of Microsatellite Instability in Asian Gastric Cancer Patients Enrolled in the ARTIST Trial. Oncology, 2019, 97, 38-43.	1.9	26
92	Detection of ERBB2 (HER2) Gene Amplification Events in Cell-Free DNA and Response to Anti-HER2 Agents in a Large Asian Cancer Patient Cohort. Frontiers in Oncology, 2019, 9, 212.	2.8	20
93	The Impact of Primary Tumor Sidedness on the Effect of Regorafenib in Refractory Metastatic Colorectal Cancer. Journal of Cancer, 2019, 10, 1611-1615.	2.5	7
94	Systematic Evaluation of Gastric Tumor Cell Index and Two-Drug Combination Therapy via 3-Dimensional High-Throughput Drug Screening. Frontiers in Oncology, 2019, 9, 1327.	2.8	5
95	Capecitabine plus Oxaliplatin as a Second-Line Therapy for Advanced Biliary Tract Cancers: A Multicenter, Open-Label, Phase II Trial. Journal of Cancer, 2019, 10, 6185-6190.	2.5	7
96	RRAD expression in gastric and colorectal cancer with peritoneal carcinomatosis. Scientific Reports, 2019, 9, 19439.	3.3	8
97	Atypical RAS Mutations in Metastatic Colorectal Cancer. JCO Precision Oncology, 2019, 3, 1-11.	3.0	1
98	MET is overexpressed in microsatellite instability-high gastric carcinoma. Pathology Research and Practice, 2019, 215, 433-438.	2.3	10
99	Safety and efficacy of trastuzumab administered as a 30-min infusion in patients with HER2-positive advanced gastric cancer. Cancer Chemotherapy and Pharmacology, 2019, 83, 501-508.	2.3	6
100	First-in-human phase I trial of anti-hepatocyte growth factor (HGF) antibody (YYB101) in refractory solid tumor patients: Integrative pathologic-genomic analysis and the final results.. Journal of Clinical Oncology, 2019, 37, 3104-3104.	1.6	2
101	ARTIST 2: Interim results of a phase III trial involving adjuvant chemotherapy and/or chemoradiotherapy after D2-gastrectomy in stage II/III gastric cancer (GC).. Journal of Clinical Oncology, 2019, 37, 4001-4001.	1.6	53
102	A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients. Cancer Research and Treatment, 2019, 51, 1128-1134.	3.0	12
103	Comparison of the 7th and the 8th AJCC Staging System for Non-metastatic D2-Resected Lymph Nodeâ€“Positive Gastric Cancer Treated with Different Adjuvant Protocols. Cancer Research and Treatment, 2019, 51, 876-885.	3.0	8
104	Multicenter retrospective analysis for efficacy and safety of liposomal irinotecan (nal-IRI) plus 5-FU/leucovorin (5-FU/LV) after progression on gemcitabine-based therapy in Korean patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): A study by Korean Cancer Study Group (KCSG).. Journal of Clinical Oncology, 2019, 37, 344-344.	1.6	1
105	The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma.. Journal of Clinical Oncology, 2019, 37, 213-213.	1.6	0
106	Comprehensive molecular characterization of clinical response in ramucirumab-treated gastric cancer patients: Phase II trial with integrated genomic profiling.. Journal of Clinical Oncology, 2019, 37, 4064-4064.	1.6	0
107	Phase 1a study results investigating the safety and preliminary efficacy of ABL001 (NOV1501), a bispecific antibody targeting VEGF and DLL4 in metastatic gastrointestinal (GI) cancer.. Journal of Clinical Oncology, 2019, 37, 3023-3023.	1.6	3
108	Detection of circulating tumor cells (CTCs) in cerebrospinal fluid of a patient with HER2-overexpressing gastric cancer and single cell analysis of intra-patient heterogeneity of CTCs. Translational Cancer Research, 2019, 8, 2107-2112.	1.0	0

#	Article	IF	Citations
109	Neutralizing antibody to FGFR2 can act as a selective biomarker and potential therapeutic agent for gastric cancer with FGFR2 amplification. American Journal of Translational Research (discontinued), 2019, 11, 4508-4515.	0.0	4
110	Phase I Trial of Anti-MET Monoclonal Antibody in MET-Overexpressed Refractory Cancer. Clinical Colorectal Cancer, 2018, 17, 140-146.	2.3	17
111	Phase I Pharmacokinetic Study of Nivolumab in Korean Patients with Advanced Solid Tumors. Oncologist, 2018, 23, 155-e17.	3.7	21
112	c-MET Overexpression in Colorectal Cancer: A Poor Prognostic Factor for Survival. Clinical Colorectal Cancer, 2018, 17, 165-169.	2.3	71
113	Efficacy of Mobile Health Care Application and Wearable Device in Improvement of Physical Performance in Colorectal Cancer Patients Undergoing Chemotherapy. Clinical Colorectal Cancer, 2018, 17, e353-e362.	2.3	62
114	The Correlation Between Serum Chemokines and Clinical Outcome in Patients with Advanced Biliary Tract Cancer. Translational Oncology, 2018, 11, 353-357.	3.7	8
115	Deep Learningâ€"Based Survival Analysis Identified Associations Between Molecular Subtype and Optimal Adjuvant Treatment of Patients With Gastric Cancer. JCO Clinical Cancer Informatics, 2018, 2, 1-14.	2.1	17
116	Low ATM expression and progression-free and overall survival in advanced gastric cancer patients treated with first-line XELOX chemotherapy. Journal of Gastrointestinal Oncology, 2018, 9, 1198-1206.	1.4	6
117	SEPROGADIC â€" serum protein-based gastric cancer prediction model for prognosis and selection of proper adjuvant therapy. Scientific Reports, 2018, 8, 16892.	3.3	7
118	Triptolide as a novel agent in pancreatic cancer: the validation using patient derived pancreatic tumor cell line. BMC Cancer, 2018, 18, 1103.	2.6	25
119	Adjuvant Chemotherapy with or without Concurrent Radiotherapy for Patients with Stage IB Gastric Cancer: a Subgroup Analysis of the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Phase III Trial. Journal of Gastric Cancer, 2018, 18, 348.	2.5	12
120	Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy. Nature Genetics, 2018, 50, 1399-1411.	21.4	145
121	Antitumor activity of sorafenib plus CDK4/6 inhibitor in pancreatic patient derived cell with KRAS mutation. Journal of Cancer, 2018, 9, 3394-3399.	2.5	5
122	NCOA4-RET fusion in colorectal cancer: Therapeutic challenge using patient-derived tumor cell lines. Journal of Cancer, 2018, 9, 3032-3037.	2.5	22
123	The impact of microsatellite instability status and sidedness of the primary tumor on the effect of bevacizumab-containing chemotherapy in patients with metastatic colorectal cancer. Journal of Cancer, 2018, 9, 1791-1796.	2.5	7
124	Necessity of adjuvant concurrent chemo-radiotherapy in D2-resected LN-positive gastric cancer. Radiotherapy and Oncology, 2018, 129, 306-312.	0.6	12
125	Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nature Medicine, 2018, 24, 1449-1458.	30.7	1,071
126	Pemetrexed Monotherapy as Salvage Treatment in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy: A Phase II Single-arm Prospective Trial. Journal of Cancer, 2018, 9, 2910-2915.	2.5	6

#	Article	IF	Citations
127	Selumetinib plus docetaxel as second-line chemotherapy in KRAS mutant, KRAS amplified or MEK signatured gastric cancer patients: First arm of the umbrella trial in GC though the molecular screening, VIKTORY trial.. Journal of Clinical Oncology, 2018, 36, 4061-4061.	1.6	3
128	First-in-human phase I trial of anti-hepatocyte growth factor (HGF) antibody (YYB101) in refractory solid tumor patients.. Journal of Clinical Oncology, 2018, 36, e14501-e14501.	1.6	1
129	VariantPlex panel to detect genomic aberrations in oncology patients with rare cancer type.. Journal of Clinical Oncology, 2018, 36, e24234-e24234.	1.6	0
130	Detection of targetable fusions using FusionPlex in oncology patients.. Journal of Clinical Oncology, 2018, 36, e24238-e24238.	1.6	0
131	A multi-center, open-label, randomized phase III trial of first-line chemotherapy with capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer. Journal of Geriatric Oncology, 2017, 8, 170-175.	1.0	39
132	Antitumor Effect of AZD4547 in a Fibroblast Growth Factor Receptor 2â€“Amplified Gastric Cancer Patientâ€“Derived Cell Model. Translational Oncology, 2017, 10, 469-475.	3.7	23
133	Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy. BMC Cancer, 2017, 17, 211.	2.6	24
134	ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer. Journal of the National Cancer Institute, 2017, 109, .	6.3	183
135	Host immune response index in gastric cancer identified by comprehensive analyses of tumor immunity. Oncolmmunology, 2017, 6, e1356150.	4.6	32
136	Clinical Application of Targeted Deep Sequencing in Solid-Cancer Patients and Utility for Biomarker-Selected Clinical Trials. Oncologist, 2017, 22, 1169-1177.	3.7	14
137	Antiemetic Corticosteroid Rotation from Dexamethasone to Methylprednisolone to Prevent Dexamethasone-Induced Hiccup in Cancer Patients Treated with Chemotherapy: A Randomized, Single-Blind, Crossover Phase III Trial. Oncologist, 2017, 22, 1354-1361.	3.7	24
138	Prevalence and detection of low-allele-fraction variants in clinical cancer samples. Nature Communications, 2017, 8, 1377.	12.8	137
139	Pilot study of sirolimus in patients with PIK3CA mutant/amplified refractory solid cancer. Molecular and Clinical Oncology, 2017, 7, 27-31.	1.0	15
140	Disappearing or residual tiny (â‰¤5Âmm) colorectal liver metastases after chemotherapy on gadoxetic acid-enhanced liver MRI and diffusion-weighted imaging: Is local treatment required?. European Radiology, 2017, 27, 3088-3096.	4.5	20
141	Clinical Outcomes of Salvage Chemoradiotherapy for Locally Recurrent Biliary Tract Cancer. Tumori, 2017, 103, 345-352.	1.1	1
142	3-Dimensional micropillar drug screening identifies FGFR2-IIIC overexpression as a potential target in metastatic giant cell tumor. Oncotarget, 2017, 8, 36484-36491.	1.8	8
143	The Clinical Impact of c-MET Over-Expression in Advanced Biliary Tract Cancer (BTC). Journal of Cancer, 2017, 8, 1395-1399.	2.5	20
144	The Impact of Microsatellite Instability Status and Sidedness of the Primary Tumor on the Effect of Cetuximab-Containing Chemotherapy in Patients with Metastatic Colorectal Cancer. Journal of Cancer, 2017, 8, 2809-2815.	2.5	18

#	Article	IF	Citations
145	The Impact of Cetuximab Plus AKT- or mTOR- Inhibitor in a Patient-Derived Colon Cancer Cell Model with Wild-Type RAS and PIK3CA Mutation. Journal of Cancer, 2017, 8, 2713-2719.	2.5	16
146	Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion. Oncotarget, 2017, 8, 15014-15022.	1.8	42
147	Prospective Feasibility Study for Using Cell-Free Circulating Tumor DNAâ€"Guided Therapy in Refractory Metastatic Solid Cancers: An Interim Analysis. JCO Precision Oncology, 2017, 1, 1-15.	3.0	31
148	Direct analysis of aberrant glycosylation on haptoglobin in patients with gastric cancer. Oncotarget, 2017, 8, 11094-11104.	1.8	21
149	Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy. Oncotarget, 2017, 8, 77415-77423.	1.8	68
150	Phase II XELOX + lapatinib treatment in HER2-amplified gastric cancer: Monitoring with serial cell-free DNA genomics.. Journal of Clinical Oncology, 2017, 35, e15610-e15610.	1.6	1
151	The implication of FLT3 amplification for FLT targeted therapeutics in solid tumors. Oncotarget, 2017, 8, 3237-3245.	1.8	20
152	Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability. Oncotarget, 2017, 8, 13320-13328.	1.8	60
153	The impact of pathologic differentiation (well/poorly) and the degree of Ki-67 index in patients with metastatic WHO grade 3 GEP-NECs. Oncotarget, 2017, 8, 73974-73980.	1.8	5
154	Correlation between MEK signature and Ras gene alteration in advanced gastric cancer. Oncotarget, 2017, 8, 107492-107499.	1.8	9
155	Development of mesenchymal subtype gene signature for clinical application in gastric cancer. Oncotarget, 2017, 8, 66305-66315.	1.8	23
156	MerTK inhibition by RXDX-106 in MerTK activated gastric cancer cell lines. Oncotarget, 2017, 8, 105727-105734.	1.8	16
157	MerTK is a novel therapeutic target in gastric cancer. Oncotarget, 2017, 8, 96656-96667.	1.8	23
158	Clinical and molecular landscape of metastatic colorectal cancer (mCRC) harboring ALK, ROS1, or NTRK 1, 2, 3 (NTRKs) rearrangements.. Journal of Clinical Oncology, 2017, 35, 589-589.	1.6	0
159	Cell free circulating tumor DNA (ctDNA) landscape in patients with advanced gastroesophageal adenocarcinoma (GEC).. Journal of Clinical Oncology, 2017, 35, 47-47.	1.6	3
160	Programmed death (PD)-ligand 1 (L1) expression and mismatch repair (MMR) deficiency across tumor types: Candidates for checkpoint inhibitor based immunotherapy.. Journal of Clinical Oncology, 2017, 35, e14622-e14622.	1.6	0
161	Post resection circulating residual disease monitoring in early stage lung and colorectal cancer patients using a circulating cell-free DNA assay with ultra-high accuracy and specificity.. Journal of Clinical Oncology, 2017, 35, e23068-e23068.	1.6	0
162	The impact of pathologic differentiation (well/ poorly) and the degree of Ki-67 index in patients with metastatic WHO grade 3 GEP-NECs.. Journal of Clinical Oncology, 2017, 35, e15686-e15686.	1.6	0

#	Article	IF	Citations
163	VIKTORY trial: Report on AZD1775/paclitaxel in TP53 mutation (+) GC, selumetinib/paclitaxel in ras aberrant GC, AZD5363/paclitaxel in PIK3CA mt and biomarker negative, savolitinib/docetaxel in met (+), and vistusertib/paclitaxel in RICTOR(+) GC.. Journal of Clinical Oncology, 2017, 35, 4024-4024.	1.6	1
164	Genomic Profiling of Metastatic Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients in the Personalized-Medicine Era. Journal of Cancer, 2016, 7, 1044-1048.	2.5	17
165	To Excavate Biomarkers Predictive of the Response for Capecitabine plus RAD001 through Nanostring-Based Multigene Assay in Advanced Gastric Cancer Patients. Journal of Cancer, 2016, 7, 2173-2178.	2.5	1
166	A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology. Cancer Research and Treatment, 2016, 48, 553-560.	3.0	19
167	The Influence of Metastatic Lymph Node Ratio on the Treatment Outcomes in the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Trial: A Phase III Trial. Journal of Gastric Cancer, 2016, 16, 105.	2.5	34
168	The prognostic role of serum C-X-C chemokine receptor type 4 in patients with metastatic or recurrent colorectal cancer. OncoTargets and Therapy, 2016, 9, 3307.	2.0	8
169	MCT4 as a potential therapeutic target for metastatic gastric cancer with peritoneal carcinomatosis. Oncotarget, 2016, 7, 43492-43503.	1.8	45
170	The Clinicopathologic Features and Treatment of 607 Hindgut Neuroendocrine Tumor (NET) Patients at a Single Institution. Medicine (United States), 2016, 95, e3534.	1.0	13
171	Role of adjuvant therapy after R0 resection for patients with distal cholangiocarcinoma. Cancer Chemotherapy and Pharmacology, 2016, 77, 979-985.	2.3	30
172	FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival. Modern Pathology, 2016, 29, 1095-1103.	5.5	70
173	Genomic Alterations in Biliary Tract Cancer Using Targeted Sequencing. Translational Oncology, 2016, 9, 173-178.	3.7	22
174	A nCounter CNV Assay to Detect HER2 Amplification: A Correlation Study with Immunohistochemistry and In Situ Hybridization in Advanced Gastric Cancer. Molecular Diagnosis and Therapy, 2016, 20, 375-383.	3.8	13
175	BEZ235 (PIK3/mTOR inhibitor) Overcomes Pazopanib Resistance in Patient-Derived Refractory Soft Tissue Sarcoma Cells. Translational Oncology, 2016, 9, 197-202.	3.7	10
176	The impact of KRAS mutations on prognosis in surgically resected colorectal cancer patients with liver and lung metastases: a retrospective analysis. BMC Cancer, 2016, 16, 120.	2.6	35
177	NanoString expression profiling identifies candidate biomarkers of RAD001 response in metastatic gastric cancer. ESMO Open, 2016, 1, e000009.	4.5	16
178	Value of FGFR2 expression for advanced gastric cancer patients receiving pazopanib plus CapeOX (capecitabine and oxaliplatin). Journal of Cancer Research and Clinical Oncology, 2016, 142, 1231-1237.	2.5	11
179	Cell-free DNA sequencing-guided therapy in a prospective clinical trial: NEXT-2 trialâ€"A feasibility analysis.. Journal of Clinical Oncology, 2016, 34, 11534-11534.	1.6	3
180	First-in-human study of HM95573, a novel oral RAF inhibitor, in patients with solid tumors.. Journal of Clinical Oncology, 2016, 34, 2570-2570.	1.6	4

#	Article	IF	Citations
181	Prognostic significance of survivin in rectal cancer patients treated with surgery and postoperative concurrent chemo-radiation therapy. Oncotarget, 2016, 7, 62676-62686.	1.8	6
182	Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors. Oncotarget, 2016, 7, 4024-4035.	1.8	36
183	Molecular characterization of colorectal cancer patients and concomitant patient-derived tumor cell establishment. Oncotarget, 2016, 7, 19610-19619.	1.8	12
184	Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer. Oncotarget, 2016, 7, 24088-24096.	1.8	15
185	Prospective phase II trial of regional hyperthermia and whole liver irradiation for numerous chemorefractory liver metastases from colorectal cancer. Radiation Oncology Journal, 2016, 34, 34-44.	1.5	10
186	The Role of Plasma Chromogranin A as Assessment of Treatment Response in Non-functioning Gastroenteropancreatic Neuroendocrine Tumors. Cancer Research and Treatment, 2016, 48, 153-161.	3.0	11
187	Value of FGFR2 expression for advanced gastric cancer patients receiving pazopanib plus CapeOX (capecitabine and oxaliplatin).. Journal of Clinical Oncology, 2016, 34, 65-65.	1.6	0
188	Role of adjuvant therapy after R0 resection for patients with distal cholangiocarcinoma.. Journal of Clinical Oncology, 2016, 34, 355-355.	1.6	4
189	Tuberous sclerosis complex 2 (TSC2) expression in hepatocellular carcinoma to predict responses to mTOR inhibitor.. Journal of Clinical Oncology, 2016, 34, e15628-e15628.	1.6	0
190	The clinicopathologic features and treatment of 607 hindgut neuroendocrine tumor (NET) patients at a single institution.. Journal of Clinical Oncology, 2016, 34, 4091-4091.	1.6	0
191	The impact of cetuximab plus AKT- or mTOR- inhibitor in patient-derived colon cancer cell model with RAS wild type and PIK3CA mutation.. Journal of Clinical Oncology, 2016, 34, e15153-e15153.	1.6	0
192	The Impact of Concomitant Genomic Alterations on Treatment Outcome for Trastuzumab Therapy in HER2-Positive Gastric Cancer. Scientific Reports, 2015, 5, 9289.	3.3	43
193	Clinical Significance of IGFBP-3 Methylation in Patients with Early Stage Gastric Cancer. Translational Oncology, 2015, 8, 288-294.	3.7	8
194	Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan. BMC Cancer, 2015, 15, 747.	2.6	10
195	Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients. Oncotarget, 2015, 6, 40360-40369.	1.8	85
196	Circulating Tumor Cells are Predictive of Poor Response to Chemotherapy in Metastatic gastric cancer. International Journal of Biological Markers, 2015, 30, 382-386.	1.8	25
197	Regorafenib as Salvage Treatment in Korean Patients with Refractory Metastatic Colorectal Cancer. Cancer Research and Treatment, 2015, 47, 790-795.	3.0	10
198	Gastrointestinal malignancies harbor actionable MET exon 14 deletions. Oncotarget, 2015, 6, 28211-28222.	1.8	57

#	Article	IF	Citations
199	Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer. Translational Oncology, 2015, 8, 40-46.	3.7	16
200	Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses. Journal of Clinical Oncology, 2015, 33, 3130-3136.	1.6	370
201	Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nature Medicine, 2015, 21, 449-456.	30.7	1,592
202	Tumour shrinkage at 6Âweeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer. BMC Cancer, 2015, 15, 530.	2.6	17
203	Effects of adjuvant radiotherapy on completely resected gastric cancer: A radiation oncologistâ€™s view of the ARTIST randomized phase III trial. Radiotherapy and Oncology, 2015, 117, 171-177.	0.6	31
204	The NEXT-2 (Next Generation Personalized Tx with Plasma DNA Genomics Trial-2 in Refractory Solid) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 e12540-e12540.	1.6	1
205	Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening. Oncotarget, 2015, 6, 24320-24332.	1.8	32
206	Patient-derived cell models as preclinical tools for genome-directed targeted therapy. Oncotarget, 2015, 6, 25619-25630.	1.8	48
207	The NEXT-1 (Next generation pErsonalized tX with mulTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis. Oncotarget, 2015, 6, 33358-33368.	1.8	24
208	PIK3CA mutation detection in metastatic biliary cancer using cell-free DNA. Oncotarget, 2015, 6, 40026-40035.	1.8	15
209	NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line. Oncotarget, 2015, 6, 39028-39035.	1.8	53
210	Can we omit prophylactic inguinal nodal irradiation in anal cancer patients?. Radiation Oncology Journal, 2015, 33, 83.	1.5	6
211	Clinical features of metastatic renal cell carcinoma patients with intrinsic resistance to sunitinib: A Korean multicenter study.. Journal of Clinical Oncology, 2015, 33, 462-462.	1.6	0
212	Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer.. Journal of Clinical Oncology, 2015, 33, 4049-4049.	1.6	2
213	Placebo-controlled, double-blinded multi-center phase III trial of XELIRI/FOLFIRI plus simvastatin in metastatic colorectal cancer.. Journal of Clinical Oncology, 2015, 33, 3576-3576.	1.6	3
214	Comprehensive genomic profiling of metastatic gastric cancer undergoing palliative chemotherapy at Samsung Medical Center using custom targeted deep sequencing (CancerSCAN^{â„¢}).. Journal of Clinical Oncology, 2015, 33, e22173-e22173.	1.6	0
215	Molecular profiling of patient derived cells (PDCs) from metastatic cancer patients using CancerSCAN: Highly profiled models to test the efficacy of genome-directed therapy in cancer.. Journal of Clinical Oncology, 2015, 33, e22241-e22241.	1.6	0
216	Pazopanib, a Novel Multitargeted Kinase Inhibitor, Shows Potent In Vitro Antitumor Activity in Gastric Cancer Cell Lines with FGFR2 Amplification. Molecular Cancer Therapeutics, 2014, 13, 2527-2536.	4.1	34

#	Article	IF	Citations
217	Successful use of pazopanib for treatment of refractory metastatic hemangiopericytoma. Clinical Sarcoma Research, 2014, 4, 13.	2.3	28
218	Simvastatin plus capecitabineâ€“cisplatin versus placebo plus capecitabineâ€“cisplatin in patients with previously untreated advanced gastric cancer: A double-blind randomised phase 3 study. European Journal of Cancer, 2014, 50, 2822-2830.	2.8	79
219	Anti-tumor efficacy of fulvestrant in estrogen receptor positive gastric cancer. Scientific Reports, 2014, 4, 7592.	3.3	24
220	High-Throughput Sequencing and Copy Number Variation Detection Using Formalin Fixed Embedded Tissue in Metastatic Gastric Cancer. PLoS ONE, 2014, 9, e111693.	2.5	34
221	CD133-positive tumor cell content is a predictor of early recurrence in colorectal cancer. Journal of Gastrointestinal Oncology, 2014, 5, 447-56.	1.4	25
222	The role of chemotherapy and/or octreotide in patients with metastatic gastroenteropancreatic and hepatobiliary neuroendocrine carcinoma. Journal of Gastrointestinal Oncology, 2014, 5, 457-62.	1.4	9
223	Dose KRAS Mutation Status Affect on the Effect of VEGF Therapy in Metastatic Colon Cancer Patients?. Cancer Research and Treatment, 2014, 46, 48-54.	3.0	10
224	The role of pazopanib in various histologic subtypes of metastatic soft tissue sarcomas.. Journal of Clinical Oncology, 2014, 32, 10586-10586.	1.6	1
225	S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: Updated results from a phase 3 trial.. Journal of Clinical Oncology, 2014, 32, 3608-3608.	1.6	0
226	Simvastatin plus capecitabine-cisplatin (XP) versus placebo plus capecitabine-cisplatin (XP) in patients with previously untreated advanced gastric cancer: A double-blind randomized phase 3 study.. Journal of Clinical Oncology, 2014, 32, 4066-4066.	1.6	16
227	Phase III trial to compare capecitabine/cisplatin (XP) versus XP plus concurrent capecitabine-radiotherapy in gastric cancer (GC): The final report on the ARTIST trial.. Journal of Clinical Oncology, 2014, 32, 4008-4008.	1.6	1
228	Transcriptome analysis of CD133-positive stem cells and prognostic value of survivin in colorectal cancer. Cancer Genomics and Proteomics, 2014, 11, 259-66.	2.0	25
229	Safety and Efficacy of Adjuvant Chemoradiation Therapy With Capecitabine After Resection of Pancreatic Ductal Adenocarcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2012, 35, 432-438.	1.3	0
230	Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy. Lung Cancer, 2012, 75, 82-88.	2.0	94
231	Impact of KRAS Mutations on Clinical Outcomes in Pancreatic Cancer Patients Treated with First-line Gemcitabine-Based Chemotherapy. Molecular Cancer Therapeutics, 2011, 10, 1993-1999.	4.1	126
232	Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy. Cancer Chemotherapy and Pharmacology, 2010, 66, 659-667.	2.3	73
233	The efficacy of frontline platinum-based combination chemotherapy in advanced adenocarcinoma of the ampulla of Vater. Medical Oncology, 2010, 27, 1149-1154.	2.5	20
234	The effect of DNA mismatch repair (MMR) status on oxaliplatin-based first-line chemotherapy as in recurrent or metastatic colon cancer. Medical Oncology, 2010, 27, 1277-1285.	2.5	24

#	Article	IF	Citations
235	Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy. Cancer, 2010, 116, 3025-3033.	4.1	34
236	The Efficacy of the Frontline Platinum-based Combination Chemotherapy in Malignant Peritoneal Mesothelioma. Japanese Journal of Clinical Oncology, 2010, 40, 1031-1036.	1.3	5
237	Prognostic Model to Predict Outcomes in Non-Small Cell Lung Cancer Patients with Erlotinib as Salvage Treatment. Oncology, 2010, 79, 78-84.	1.9	14